ALAUNOS THERAPEUTICS, INC.

Analyst Reco. Alaunos Therapeutics, Inc.

Equities

TCRT

US98973P2002

Market Closed - Nasdaq Other stock markets 01:30:00 18/06/2024 am IST			5-day change	1st Jan Change
0.96 ^USD	+4.35%		-7.69%	-9.48%

10/06	BioSig Technologies Appoints Ferdinand Groenewald as Interim CFO	MT
15/05	Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

HC Wainwright Downgrades Alaunos Therapeutics to Neutral From Buy	16/23/16	MT
Laidlaw Downgrades Alaunos Therapeutics to Hold From Buy	15/23/15	MT
Wells Fargo Assumes Alaunos Therapeutics at Overweight with $3 Price Target	04/22/04	MT
Cantor Fitzgerald Assumes Alaunos Therapeutics at Overweight with $3 Price Target	15/22/15	MT
Wells Fargo Upgrades Alaunos Therapeutics to Overweight From Equalweight	04/22/04	MT
ZIOPHARM ONCOLOGY : Lake Street Adjusts ZIOPHARM Oncology's Price Target to $3.50 From $7, Maintains Buy Rating	10/21/10	MT
ZIOPHARM ONCOLOGY : Raymond James Downgrades ZIOPHARM Oncology to Market Perform From Outperform; Price Target is $3	10/21/10	MT
ZIOPHARM ONCOLOGY : Raymond James Adjusts Price Target on ZIOPHARM Oncology to $4 From $5.50, Maintains Outperform Rating	07/21/07	MT
ZIOPHARM ONCOLOGY : Jefferies Downgrades ZIOPHARM Oncology to Hold Rating From Buy, Adjusts Price Target to $5 From $7	12/21/12	MT
ZIOPHARM ONCOLOGY : HC Wainwright Downgrades ZIOPHARM Oncology to Neutral From Buy	01/21/01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer